Drug Repositioning Discovery for Early- and Late-Stage Non-Small-Cell Lung Cancer

Table 10

The number of common drugs for early-stage and late-stage using the enrichment score (ES) and cMap value (less than 0.1) for meta-analysis.

Effect size	ES		value
	Early-stage	Late-stage	Early-stage	Late-stage
ES
Early-stage		0.421	0.156	0.136
Late-stage	16		0.132	0.217
value < 0.1
Early-stage	5	5		0.182
Late-stage	6	10	6